Medissey-Rebomed, Bio and Medical Device Joint Marketing Business Agreement

Han Jong-hyun, CEO of Medisay (left), Shin Bong-geun, CEO of Revomed.

[Asia Economy Reporter Lee Gwan-joo] Dongwha Pharm affiliate Medisay announced on the 30th that it has signed a business agreement with Levomed for joint marketing of bio and medical devices.

Through this agreement, Medisay will have the opportunity to diversify its business portfolio by jointly developing and marketing various medical devices with Levomed. Levomed expects to expand sales and strengthen research and development (R&D) capabilities by leveraging Medisay's global sales network.

Medisay is the number one company in the domestic spinal implant sector and operates global businesses not only in domestic orthopedics and neurosurgery but also through overseas subsidiaries in the United States, Chile, and other countries. Dongwha Pharm acquired Medisay in 2020.

Levomed is a company that develops bio kits for extracting autologous stem cells and medical laser devices.

This content was produced with the assistance of AI translation services.